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Abstract: Epithelial ovarian cancer (EOC) is one of the deadliest gynecological malignancies.
Topotecan remains an essential tool in second-line therapy; even so, most patients develop resistance
within a short period of time. We aimed to identify biomarkers of topotecan resistance by using gene
expression signatures derived from patient specimens at surgery and available subsequent responses
to therapy. Gene expression was collected for 1436 patients and 10,103 genes. Based on disease
progression, patients were categorized as responders/nonresponders depending on their progression
free survival (PFS) state at 9, 12, 15 and 18 months after surgery. For each gene, the median expression
was compared between responders and nonresponders for two treatment regimens (chemotherapy
including/excluding topotecan) with Mann–Whitney U test at each of the four different PFS cutoffs.
Statistical significance was accepted in the case of p < 0.05 with a fold change (FC) ≥ 1.44. Four genes
(EPB41L2, HLA-DQB1, LTF and SFRP1) were consistently overexpressed across multiple PFS cutoff
times in initial tumor samples of patients with disease progression following topotecan treatment.
A common theme linked to topotecan resistance was altered immune modulation. Genes associated
with disease progression after systemic chemotherapy emphasize the role of the initial organization
of the tumor microenvironment in therapy resistance. Our results uncover biomarkers with potential
utility for patient stratification.
Keywords: ovarian carcinoma; resistance; biomarker; gene expression; gene arrays; survival;
tumor microenvironment
1. Introduction
Ovarian cancer accounts for 2.5% of cancer diagnoses and 5% of cancer-related deaths among
women worldwide. Despite gradually descending rates in some developed countries [1], incidence
rates are on the rise in ageing societies [2]. At the same time, mortality rates have not improved
significantly over the past decades. The most common subgroup, epithelial ovarian cancer (EOC),
represents about 90% of all ovarian cancer cases. A lack of specific symptoms, late diagnoses and
intrinsic and acquired resistance to most conventional chemotherapies designate EOC as one of the
deadliest cancers among women, with 5-year survival rates as low as 50% [3]. Over 70% of patients are
diagnosed in an advanced disease stage with intraperitoneal dissemination [4]. The most common
subtype, serous ovarian carcinoma, represents about 50% of all EOC, with most diagnosed at stage III
(51%) or stage IV (29%), with 5-year survival rates of 20%, reflecting the subtype’s aggressive nature [1].
Primary treatment consists of surgery and platinum-based combination chemotherapy, usually
involving cisplatin [5,6]. High initial response rates are followed by frequent disease recurrence, and
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most original responders eventually develop resistance to conventional therapies [7,8]. Second-line
treatment depends on the patient’s response to the first line and involves medicines such as topotecan,
doxorubicin, paclitaxel, bevacizumab and gemcitabine [9–12]. Nevertheless, only 15–35% of patients
respond to second-line therapy; thus, the development of efficacious salvage therapies is an unmet
need, as is the identification of treatment-resistance biomarkers.
Topotecan is a semi-synthetic derivative of camptothecin that inhibits the activity of DNA
topoisomerase I, which is required for DNA replication and transcription. Topotecan mimics a DNA
base pair that binds to and stabilizes the enzyme–DNA complex, eventually leading to double-stranded
DNA breaks and cellular death [13]. Topotecan was approved as a second-line therapy for relapsed
EOC in 1996, with demonstrated antitumor activity in platinum-sensitive, platinum-resistant and
paclitaxel-resistant tumors with a predictable and manageable toxicity profile [14], and to date it
remains an important treatment option. Nonetheless, cancer cells develop various mechanisms to
evade topotecan, such as by novel mutations or down-regulation of the topoisomerase gene [15].
Increased expression of collagen genes might also inhibit drug penetration to the tumor tissue [16],
although their causative role in topotecan resistance has not been validated. The active removal of
topotecan from cancer cells is also under intense scrutiny [17].
With most EOC patients developing resistance against systemic chemotherapy, biomarkers
predicting specific treatment responses with potential utility for patient stratification for personalized
therapeutic approaches are much sought after. We aimed to identify differentially expressed genes in
patient specimens collected at surgery with an accessible response to systemic therapy, with particular
focus on topotecan-containing regimens. Since topotecan is administered as the second line to a heavily
pretreated population, patients not treated with topotecan may assist in revealing differential gene
expression across treatment modalities. The initial gene expression in tumor specimens of subsequent
nonresponders (defined as patients with disease progression until a certain cutoff time after surgery)
allows the identification of upregulated genes associated with disease relapse.
Our findings suggest that cancer progression may be related to preceding alterations in the
tumor microenvironment. Resistance associated with systemic chemotherapy seems to be linked to
already present ECM and cytoskeleton modifications in initial tumor samples, while altered immune
modulation is indicated in treatment-naïve specimens of patients who progressed on topotecan.
The presented bioinformatics-based concept helps to identify biomarkers of therapy resistance
with potential utility for patient stratification, may be adapted for other treatments or tumor types,
and provides a viable starting point for subsequent functional investigations.
2. Results
2.1. Transcriptomic Database for Biomarker Selection
Data from 1436 patients diagnosed with EOC were available from 10 datasets from the Gene
Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/) and The Cancer Genome Atlas
(TCGA) (https://cancergenome.nih.gov/) repositories [18–27]. The majority (~77%) of EOC patients
were diagnosed with serous subtype, and 64% of patients were identified with a stage III disease
(Figure 1A). About half of patients had undergone optimal tumor debulking before chemotherapy
initiation. The majority of patients (87.7%) received platinum-based chemotherapy, while about half of
them received this in combination with taxol. Less than 10% of patients received either gemcitabine or
topotecan, and only 3.5% of patients were treated with the targeted angiogenesis inhibitor bevacizumab.
Over 26% of patients relapsed until the 12-month cutoff, and in total two-thirds of patients progressed
during the median follow-up of 16.3 months (Table 1).
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Table 1. Clinical characterization of the entire epithelial ovarian cancer (EOC) dataset and the
117 patients receiving topotecan.
Characteristics All EOCPatients (%)
Topotecan-Treated
EOC Patients (%)
Stage
I 6.7 0.9
II 4.7 2.6
III 64.0 84.6
IV 11.3 11.1
N/A 13.4 0.9
Grade
I 2.6 16.2
II 17.8 80.3
III 58.3 0.9
IV 1.3 2.6
N/A 20.0
Subtype
Serous 76.9 100
Endometrioid 3.6
Clear 2.2
N/A 17.4
Debulking
Optimal 48.5 74.4
Suboptimal 32.0 22.2
N/A 19.5 3.4
Progression (median follow up16.3 months) 68.1
(median follow
up 14.8 months) 88.0
Treatment
Platinum 87.7 100
Taxol 49.8
Combined platinum and taxol 48.6 75.2
Bevacizumab 3.5 12.8
Docetaxel 7.4 30.8
Gemcitabine 9.1 62.4
Paclitaxel 15.9 25.6
Topotecan 8.2 100
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epithelian ovarian cancer dataset and in the sub-cohort treated with systemic therapy including 
topotecan. (A) Proportion of responders (grey)/nonresponders (blue) to systemic chemotherapy 
including/excluding topotecan at the four progression free survival (PFS) cutoff times in topotecan-
untreated (B) and -treated (C) patients. 
2.2. Upregulated Genes among Nonresponders Treated with Chemotherapy Excluding Topotecan 
Out of the available 1436 patients, 1319 were treated with systemic chemotherapy, not including 
topotecan. Some patients had to be excluded from subsequent analyses due to incomplete follow-up 
(Figure 2). Out of systemic chemotherapy-treated patients, 17.3% progressed until the 9th month and 
45.6% until the 18th month of PFS cutoff after surgery (Figure 1B). 
 
 
Figure 2. Analysis workflow for the database setup and the number of systemic chemotherapy-treated 
(including/excluding topotecan) patients at each PFS-cutoff. 
We compared the gene expression derived from initial tumor samples between subsequent 
responders and nonresponders at each of the four PFS cutoff points, and determined significantly 
Figure 1. Patient characteristics including stage, grade and histological subtype across the entire
epithelian ovarian cancer dataset and in the sub-cohort treated with systemic therapy including topotecan.
(A) Proportion of responders (grey)/nonresponders (blue) to systemic chemotherapy including/excluding
topotecan at the four progression free survival (PFS) cutoff times in topotecan-untreated (B) and -treated
(C) patients.
2.2. Upregulated Genes among Nonresponders Treated with Chemotherapy Excluding Topotecan
Out of the available 1436 patients, 1319 were treated with systemic chemotherapy, not including
topotecan. Some patients had to b excluded from subsequent analyses due t incomplete follow-up
(Figure 2). Out of systemic chemoth rapy-treated patients, 17.3% progressed until the 9th m nth and
45.6% until the 18th month of PFS cutoff after surgery (Figure 1B).
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 17 
 
 
Figure 1. Patient characteristics including stage, grade and histological subtype across the entire 
epithelian ovarian c ncer data et and in the sub-cohort treated with systemic the apy including 
topotecan. (A) Proportion of respond rs (grey)/nonresponders (blue) to systemic chemotherapy 
including/excluding topotecan at the four progression free survival (PFS) cutoff times in topotecan-
untreated (B) and -treated (C) patients. 
2.2. Upregulated Genes among Nonresponders Treated with Chemotherapy Excluding Topotecan 
Out of the available 1436 patients, 1319 wer  treated with systemic chemotherapy, ot including 
topotecan. Some patients had to be excluded from subsequent analyses due to incomplete follow-up 
(Figure 2). Out of systemic chemotherapy-treated patients, 17.3% progressed until the 9th month and 
45.6% until the 18th month of PFS cutoff after surgery (Figure 1B). 
 
 
Figure 2. Analysis workflow for the database setup and the number of systemic chemotherapy-treated 
(including/excluding topotecan) patients at each PFS-cutoff. 
We compared the gene expression derived from initial tumor samples between subsequent 
responders and nonresponders at each of the four PFS cutoff points, and determined significantly 
Figure 2. Analysis workflow for the database setup and the number of systemic chemotherapy-treated
(including/excluding topotecan) patients at each PFS-cutoff.
We compared the gene expression derived from initial tumor samples between subsequent
responders and nonresponders at each of the four PFS cutoff points, and determined significantly
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upregulated genes in specimens of nonresponders (at p < 0.05; FC ≥ 1.44; mean expression in at least
one cohort > 600). Altogether, 27 genes were overexpressed in tumor specimens of patients who
progressed after systemic adjuvant therapy excluding topotecan until 18 months post-surgery. Out of
the 27 genes, 16 were significantly upregulated in patients who relapsed until 9 months post-surgery,
13 genes were significant when PFS cutoff was set at 12 months, 20 genes when the cutoff was set
at 15 months, and 18 genes when the cutoff time between nonresponders and responders was set at
18 months (Figure 3).
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Figure 3. List of genes with higher expression in specimens of nonresponders who received systemic
chemotherapy excluding topotecan. The figure is color-coded for expression (high-red), fold change
(high-red) and p-values (low-red).
For 18 genes, the association between gene upregulation and subsequent disease progression held
through multiple cutoff times, and for 9 genes (AEBP1, COL10A1, COL1A1, COL5A2, EPYC, FAP, IGF1,
THBS2 and TIMP3), the association remained significant at all four PFS cutoffs between responders
and nonresponders (Figure 3).
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We subjected the 27 upregulated genes to the gene enrichment analysis by Database for Annotation,
Visualization and Integrated Discovery (DAVID) Bioinformatics Resources 6.8. Gene sets related to
extracellular matrix and collagen fibril organization, skeletal system development, cellular response
to fibroblast growth factor stimulus and collagen catabolic process were enriched significantly (after
Bonferroni correction) in tumor samples derived from patients who eventually became resistant to
systemic chemotherapy excluding topotecan. The results, grouped by relevant function, are listed in
Table 2.
Table 2. Functional grouping of significantly upregulated genes in tumor samples of patients with
subsequent resistance to systemic chemotherapy, excluding topotecan. Gene ontology analysis is based
on 27 genes for which the association between gene upregulation and subsequent disease progression
held through different cutoff times.
Term Count p-Value Genes Bonferroni
Extracellular
matrix organization 9 3.90 × 10−10
COL5A1, COL1A1, LOX, POSTN, COL5A2,
COL10A1, LUM, SERPINE1, MFAP5 1.31 × 10−7
Collagen fibril organization 5 3.58 × 10−7 COL5A1, COL1A1, LOX, COL5A2, LUM 1.20 × 10−4
Skeletal system development 6 1.93 × 10−6 IGF1, COL1A1, POSTN, COL5A2,COL10A1, AEBP1 6.45 × 10−4
Cellular response to fibroblast
growth factor stimulus 4 1.30 × 10−5 COL1A1, POSTN, SNAI2, CDC5L 4.35 × 10−3
Collagen catabolic process 4 1.29 × 10−4 COL5A1, COL1A1, COL5A2, COL10A1 4.23 × 10−2
2.3. Topotecan-Treated EOC Population
As topotecan is administered in second-line treatment, a more aggressive subtype and advanced
stage, a heavy treatment load and poor survival outcome were expected in this patient cohort (n = 117).
All topotecan-treated patients were diagnosed with serous EOC (Figure 1A). Consistent with this
subtype’s aggressive nature, most patients (~85%) were recognized with a clinical stage III disease
(Figure 1A). Three-quarters of patients underwent successful tumor debulking before starting on
adjuvant systemic treatment. All topotecan-treated patients received platinum-based chemotherapy in
the first line, and 75% of them obtained combined platinum/taxol treatment. Besides topotecan, the
second-line treatments also involved gemcitabine (~62%), docetaxel (~31%), paclitaxel (~26%) and
bevacizumab (~13%) (Table 1). During the median follow-up time of the entire cohort (14.8 months),
88% of topotecan-treated patients relapsed.
2.4. Upregulated Genes in Topotecan-Treated EOC Population
Out of the available 117 topotecan-treated patients, 18.8% were identified as non-responders by
9 months, and 36.7% of patients relapsed by 12 months after surgery. Survival data were available
for 115 patients at 15 and 18-month cutoff times, out of which 52.1% of patients progressed until the
15th month and 60.9% until the 18-month PFS cutoffs (Figure 1C). We compared the expression of the
10,103 genes between specimens of responders and nonresponders determined at each PFS cutoff.
In total, 10 upregulated genes were identified in nonresponders treated with topotecan-containing
chemotherapy: six genes (CD200, GOLPH3L, HLA-DQB1, OVGP1, SCGB2A1 and SLC25A38) were
significantly upregulated in tumors of patients with subsequent disease progression when PFS cutoff
was set at 9 months, four genes (EPB41L2, HLA-DQA1, HLA-DQB1 and SFRP1) when the cutoff was at
12 months, two (SFRP1 and LTF) genes at 15 months and three genes (SFRP1, LTF and EPB41L2) when
the cutoff was at 18 months (Table 3, Figure 4A).
The combined expression of genes upregulated at 12, 15 and 18-month cutoffs was associated
with significantly worse PFS among topotecan-treated patients (Figure 4B), but the association was not
significant for the combined gene expression at 9 months (p > 0.1).
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Figure 4. Significantly upregulated genes at the four different progression free survival (PFS) cutoff
points in the topotecan-treated patient cohort (A). Combined expression of significant upregulated genes
at 12, 15 and 18-month PFS cutoffs associated with disease progression in the group of topotecan-treated
patients (B). Combined receiver operator characteristic (ROC) curve for EPB41L2, HLA-DQB1 and
SFRP1, consistently overexpressed in initial tumor samples of subsequent nonresponders to topotecan,
which were also significant at the 12-month PFS cutoff (C).
Four genes (EPB41L2,HLA-DQB1, LTF and SFRP1) were consistently overexpressed in initial tumor
samples of subsequent nonresponders across multiple PFS cutoff times (Figure 5). High expressions of
EPB41L2, HLA-DQB1, LTF and SFRP1 were persistently associated with significantly worse PFS among
topotecan-treated EOC patients (Figure 5). There was no correlation in the expression of EPB41L2,
HLA-DQB1, LTF and SFRP1 genes (Spearman’s rank correlation, p > 0.1). There was also no association
between treatment response and different stages of EOC (χ2 test, p = 0.588).
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Table 3. Significantly upregulated genes in tumor samples of subsequent nonresponders identified at different cutoff times (9, 12, 15 and 18 months after surgery)
treated with systemic chemotherapy including topotecan. The four highlighted genes were significantly upregulated in tumor samples of subsequent nonresponders
across multiple PFS cutoff times. AUC: area under the curve.
PFS Cutoff (Months) Gene Symbol Mean Expression(Nonresponder)
Mean Expression
(Responder) Fold Change Mann–Whitney p-Value AUC AUC p-Value
9 CD200 1718.6 1165.7 1.47 2.13 × 10−2 0.658 8.20 × 10−3
12 EPB41L2 1918.2 1160.9 1.65 1.24 × 10−2 0.639 6.90 × 10−3
18 EPB41L2 1703.6 1036.1 1.64 7.70 × 10−3 0.648 1.80 × 10−3
9 GOLPH3L 2289.1 1583.0 1.45 2.34 × 10−2 0.656 6.50 × 10−3
12 HLA-DQA1 1353.5 908.2 1.49 1.94 × 10−2 0.63 8.30 × 10−3
9 HLA-DQB1 1243.8 830.4 1.50 2.42 × 10−2 0.655 8.20 × 10−3
12 HLA-DQB1 1202.6 737.0 1.63 4.45 × 10−3 0.658 1.20 × 10−3
15 LTF 1034.3 316.5 3.27 4.38 × 10−2 0.609 1.90 × 10−2
18 LTF 908.5 352.8 2.58 4.13 × 10−2 0.613 1.70 × 10−2
9 OVGP1 1975.9 362.2 5.46 7.95 × 10−3 0.682 5.90 × 10−3
9 SCGB2A1 11433.0 7001.9 1.63 3.31 × 10−2 0.646 2.00 × 10−2
12 SFRP1 882.5 401.5 2.20 2.46 × 10−2 0.625 1.20 × 10−2
15 SFRP1 727.7 393.8 1.85 1.49 × 10−2 0.632 5.80 × 10−3
18 SFRP1 679.6 394.3 1.72 3.23 × 10−2 0.619 1.40 × 10−2
9 SLC25A38 1838.8 1101.3 1.67 2.55 × 10−2 0.707 1.90 × 10−4
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Figure 5. onsistently upregulated genes in EOC tumor specimens associated with subsequent
resistance to topotecan-containing systemic chemotherapy. The high expression of the identified genes
is associated with worse progression-free survival among topotecan-treated patients.
Combined area under the curve (AUC) values for EPB41L2, HLA-DQB1 and SFRP1, which were
consistently overexpres ed in initial tumor samples of subsequent nonresponders and significant at
the 12-month cutoff, are presented in Table 4 and Figure 4C.
Table 4. Combined AUC values involving thre genes (EPB41L2, HLA-DQB1 and SFRP1) which were
consistently overexpres ed in initial tumor samples of subsequent nonresponders to topotecan and
also significant at the 12-month PFS cutoffs.
Gene Combinations AUC Values p-Values
HLA-DQB1 + EPB41L2 0.679 0.001
HLA-DQB1 + SFRP1 0.696 <0.001
EPB41L2 + SFRP1 0.675 0.002
HLA-DQB1 + EPB41L2 + SFRP1 0.71 <0.001
None of the ten upregulated genes identified in nonresponders treated with topotecan-containing
chemotherapy overlapped to genes upregulated in nonresponders treate with syst mic chem therapy
excludi g topotecan.
3. Discussion
Our results support the significance of initial tumor microenvironment organization in subsequent
therapy resistance. The tumor microenvironment is a heterogeneous cell population composed
of stromal, tumor and immune cells and an extracellular matrix (ECM) [28], where tumor cells
and the surrounding environment communicate substantially and their co-evolution promotes
tumor growth and progression [29]. In relapsed patients treated with chemotherapy (excluding
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topotecan), upregulated genes were specific to the extracellular matrix and collagen fibril organization,
skeletal system development, cellular response to fibroblast growth factor stimulus and collagen
catabolic processes.
Cancer-associated fibroblasts (CAF) are the most prominent stromal cell types that release a
variety of factors into the tumor microenvironment that may promote ECM remodeling [30], and
contribute to drug-resistance acquisition with a negative impact on clinical outcome [31]. A useful
marker indicating the presence of CAFs, especially myofibroblasts, is the high intratumoral expression
of fibroblast activation protein-α (FAP). FAP-expressing cells also exert an immune-suppressive
function in the tumor microenvironment [32]. In our analysis, FAP was consistently overexpressed in
treatment-naïve specimens of patients with subsequent relapse after cytotoxic chemotherapy, along
with genes that contribute to EMT, angiogenesis, invasion and metastasis, conforming to previous
findings [23,33,34]. Moreover, there was a compelling overlap between our list of upregulated genes in
chemotherapy-resistant patients and the collagen-remodeling gene signature associated with poor
outcomes in serous EOC [35].
Strikingly, a different set of genes was upregulated in initial samples of subsequent nonresponders
to topotecan. Topotecan, with its well-tolerated toxicity profile, remains an important tool in the
treatment of recurrent EOC, administered to an already pretreated population resistant to first-line
chemotherapy. However, most patients eventually progress with limited options for salvage therapies.
In our dataset, a high initial expression of EPB41L2, HLA-DQB1, LTF and SFRP1 was linked to
subsequent shorter progression-free survival. The overexpression of immune-function related genes,
such as HLA-DQA1, HLA-DQB1 and LTF, suggests the significance of immune modulation, while
additional upregulated genes were linked to altered cell adhesion (CD200), Golgi to plasma membrane
protein transport (GOLPH3L), androgen signaling (SCGB2A1), heme biosynthesis and erythrocyte
differentiation (SLC25A38).
These findings further reinforce the role of the altered tumor-microenvironment in subsequent
therapy resistance. The spectrum of alterations present in treatment-naïve tumor samples affecting
response to chemotherapy (ECM and cytoskeletal remodeling) or topotecan (immune modulation)
highlight potential mechanisms of the evolution of cancer to a more aggressive form.
The class II HLA molecules of the human major histocompatibility complex (MHC) are expressed
in macrophages, B-lymphocytes and dendritic cells, with a central role of presenting antigenic peptides
derived from exogenous proteins to cognate CD4+ T-cells. HLA class II molecules are heterodimers
and HLA-DQA1 and HLA-DQB1 encode members of the alpha and beta chain paralogs, respectively.
During HLA molecule synthesis, class II α and β chains dimerize in the endoplasmic reticulum and
form a nonameric complex with the invariant chain (Ii), which contributes to proper folding and
prevents premature peptide loading [36]. The expression of HLA class II antigens is tightly regulated to
ensure an adequate immune response towards pathogens, virally transformed and malignant cells [37].
Growing evidence indicates that the expression of HLA class II antigens by tumor cells alters
their immunogenicity [38]. The expressed HLA class II molecules could make the tumor cells more
detectable and eliminable for the immune system. Accordingly, constitutive HLA class II antigen
expression is associated with a favorable prognosis in numerous solid tumors [39,40]. However,
consistent with our results, HLA upregulation may be coupled with a lack of immune-mediated
tumor eradication: constitutive HLA class II antigen expression has been associated with increased
progression in melanomas [41,42] and linked to more frequent metastasis, recurrence, poor response to
chemotherapy and dismal outcome in osteosarcoma [43]. In the ovarian carcinoma microenvironment,
only T cells are able to spontaneously suppress tumor progression [44]. Consistent HLA class II
overexpression in initial specimens of topotecan-treated and relapsed EOC patients suggests that HLA
class II-mediated immune-escape deserves further consideration as a mechanism of therapy resistance.
Apart from antigen presentation, HLA class II components may have a role in tumorigenesis,
as certain alleles or polymorphisms have been shown to contribute to cancer susceptibility [45].
A significant association has been established between the presence of HLA-class II haplotypes
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DRB1*0301-DQA1*0501-DQB1*0201 and DRB*1001-DQA1*0101-DQB1*0501 and increased risk of
ovarian cancer [46]. In a sample of ten Caucasian ovarian cancer patients, chromosomal changes,
especially gene or DNA amplifications were frequent in the HLA class II region, although copy number
changes of 6p21.3 were inversely correlated to expression levels of HLA class II molecules [47].
An important component of the non-specific immune system is the protein product of
lactotransferrin (LTF) that participates in first-line microbial host-defense and iron homeostasis [48].
LTF, also called lactoferrin, is an iron-binding glycoprotein found at the mucosal surface, also abundant
in specific granules of neutrophils with antiviral, antimicrobial and antifugal properties [48]. Lactoferrin
is up-regulated during inflammation; it activates the innate immune system by surface receptors
generating LTF-containing immune complexes (LTF-IC) that trigger infiltration by monocytes and
macrophages [49]. LTF-ICs are also able to switch anti-inflammatory M2 macrophages to an M1-like
phenotype with pro-inflammatory properties [50]. Lactoferrin sequesters free iron and, by removing
this essential substrate, fights bacterial growth [51] and contributes to the iron regulatory gene signature,
utilized for the identification of high-risk breast cancer patients [52]. The consistent upregulation of LTF
may suggest an inflamed tumor microenvironment, indicating the possibility of microbial infections
and/or potentially altered iron metabolism that may contribute to subsequent resistance to systemic
topotecan administration. LTF also has the capacity to inhibit proliferation and induce apoptosis in
tumor cells [53]. Alternatively, since topotecan generally affects rapidly proliferating cancerous cells,
one can speculate that tumors with increased LTF expression and reduced proliferation may show
innate resistance to the effects of topotecan.
Another potential tumor suppressor upregulated in topotecan-resistant patients is SFRP1,
a member of the secreted frizzled-related protein (SFRP) gene family that shares sequence homology
with Fzd receptors, can sequester Wnt ligands and antagonize Wnt signaling [54]. The tumor
suppressor function of SFRPs varies between different SFRP members and different cancer types [55,56].
In high-grade serous ovarian carcinomas, SFRP1 protein loss has been described, and reduced
expression was associated with promoter methylation [57], although the study did not investigate
treatment effects. In rat bone marrow cells, SFRP1 expression was profoundly increased after a single
dose of topotecan–oxaliplatin combination therapy [58]. In contrast, in our dataset, SFRP1 mRNA was
already high prior to topotecan treatment in subsequent nonresponders. The overexpression of SFRP1
has been described in basal-like breast cancer [59] and associated with the presence of lymph node
metastases and decreased overall survival in gastric cancer [60]. Our findings suggest that SFRP1 may
act as an oncogene in topotecan-treated patients, or alternatively, tumor cells overexpressing SFRP1
may be innately more resistant to the elimination of rapidly proliferating tumor cells.
Erythrocyte membrane protein band 4.1 like 2 (EPB41L2) gene encodes the protein 4.1G, a member
of the 4.1 superfamily of scaffold proteins with three additional paralogues. Contrary to the other
paralogues, 4.1G is a prognostic biomarker of worse survival within our dataset of ovarian cancer
patients (data not shown); this association was also confirmed by The Human Protein Atlas [61].
Thus, EPB41L2 may behave as an oncogene in ovarian cancer, although the association requires
further investigations.
Our approach has several limitations. The presence of shared genes across various cutoff times
may be attributed to similar evolutionary forces, but the results do not provide evidence for such
mechanisms. Instead, we present a promising starting point for subsequent investigations focusing on
underlying processes. The bottom line is the concept that could be adapted for other treatments or tumor
types. Moreover, upregulated genes associated with progression at 9 months may be more relevant
compared to genes linked to relapse at 18 months, but our analysis is unable to differentiate between
them. Finally, there are some inconsistencies in the patterns of gene overexpressions. For example,
EPB41L2 is upregulated at 12 and 18 but not at 15 months, which is possibly caused by the relatively
small sample size. As more data become available, we hope to correct such inconsistencies.
In summary, our approach suggests directions to study treatment-dependent mechanisms of
therapy resistance. The common pattern among the consistently overexpressed genes in topotecan-
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resistant patients is that many of them function as tumor suppressors in other types of solid tumors,
drawing attention to the specific organization of signaling networks in ovarian cancer. The identified
transcriptomic perturbations may assist patient stratifications and offer avenues for future studies to
unveil mechanisms of topotecan resistance, with particular focus on the altered immune environment.
4. Methods
4.1. Database Setup
We searched GEO (http://www.pubmed.com/geo) and TCGA (http://cancergenome.nih.gov) to
identify datasets suitable for the analysis. In this, the keywords “ovarian”, “cancer”, “survival”,
“GPL96”, “GPL570” and “GPL571” were used. The three geo platforms (GPL) refer to three Affymetrix
gene array platforms which share identical probe sets to measure gene expression. Non-overlapping
probe sets were not utilized in our analysis. Only publications with available raw microarray gene
expression data, clinical treatment and response or survival information, and at least 20 patients
were included.
The raw CEL files were MAS5 normalized in the R statistical environment (http://www.r-project.
org) using the Affy Bioconductor library (Figure 2) [62]. A second scaling normalization was performed
to set the mean expression on each chip to 1000 to reduce batch effects [63].
4.2. Clinical Data
Clinical data were collected manually for each sample. Each dataset was validated by at least two
researchers (J.T.F. and B.G.) to ensure the reliable designation of clinical characteristics for each patient
sample. We studied the association between initial gene expression and subsequent disease-progression
in patients treated with systemic chemotherapy including/excluding topotecan. For this, we utilized the
presence/absence of disease progression to split patients into two cohorts (nonresponders/responders)
at each of the time points of 9, 12, 15 and 18 months after surgery for both (systemic chemotherapy
including/excluding topotecan) treatment regimens.
4.3. Gene Selecting Algorithm
Information about gene expression for the 1436 patients was available for 10,103 unique genes.
For each gene, the median expression was compared between responders and non-responders for each
treatment type (chemotherapy including/excluding topotecan) with Mann–Whitney U test and receiver
operator characteristics (ROC) at each progression-free survival (PFS) cutoff (9, 12, 15 and 18 months
after surgery). Statistical significance was accepted in the case of p < 0.05 and fold change (FC) ≥ 1.44.
Only genes with a mean expression above 600 were considered to be meaningful. The package “roc” was
used to calculate the area under the curve (AUC) and significance [64] (http://www.bioconductor.org).
For each cutoff time, we had to exclude a fraction of the patients from the analysis whose event-free
follow up did not reach the cutoff (e.g., follow up was shorter than 12 months at the 12-month PFS cutoff
and no progression occurred during this period). The final number of responders and nonresponders
for each treatment type and cutoff is illustrated in Figure 2.
Finally, gene enrichment analysis was performed by the Database for Annotation, Visualization
and Integrated Discovery (DAVID) Bioinformatics Resources 6.8 to assess the biological meaning of
functionally related gene groups [65]. Bonferroni correction was applied to correct for multiple testing.
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